Collateral Nervous Damages After Cryoballoon Pulmonary Vein Isolation

The Future of Pulmonary Vein Isolation - Single-shot Devices, Remote Navigation or Improving Conventional Radiofrequency Delivery by Contact Monitoring and Lesion Characterisation?

Pulmonary vein isolation is the main goal of atrial fibrillation (AF) ablation to date. Lack of isolation is associated with an increased risk of AF recurrences. Precise navigation to specific target sites, catheter stability and appropriate contact force are requisites for effective radiofrequency applications. Conventional manual-guided point-by-point radiofrequency energy delivery shows limitations to reach them, especially when performed by non-experienced electrophysiologists. New technological alternatives are rapidly arising and becoming clinically available to overcome some of the manual-guided radiofrequency delivery shortcomings. Here, we review the most recent clinical data, potential advantages, shortcomings and future directions of the new ablation strategies for pulmonary vein isolation.

Feasibility of mitral isthmus and left atrial roof linear lesions using an 8 mm tip cryoablation catheter

BACKGROUND

Left atrial linear lesions are part of the ablation strategy for persistent atrial fibrillation. Radiofrequency (RF) energy is the standard energy modality. Pulmonary vein (PV) balloon cryoablation has similar success rates to RF energy but is unsuitable for linear lesions. This study assessed the feasibility and safety of left atrial linear lesions using an 8 mm tip cryoablation catheter.

METHODS AND RESULTS

Consecutive patients undergoing left atrial ablation procedures for paroxysmal or persistent atrial fibrillation were studied. An 8 mm tip focal cryoablation catheter was used to create mitral isthmus and left atrial roof linear lesions and compared to a matched cohort undergoing RF ablation. A total of 21 patients (54 ± 11 years, 14 male), 15 undergoing de novo procedures using a dual console technique (simultaneous focal catheter and cryoballoon PV ablation) and 6 redo procedures (single console and focal catheter) were studied. Mitral isthmus ablation was successful in 19/21 (91%) with a mean total ablation time of 32.5 ± 2.9 minutes. Roof line ablation was successful in 18/19 with a mean ablation time of 15.6 ± 6.0 minutes. Success rates were similar but ablation times were longer than those in the matched RF group. Epicardial ablation in the coronary sinus was required less often with cryoablation (11/21 vs 17/21, P < 0.05). There were no complications.

CONCLUSION

Left atrial linear lesions with an 8 mm tip cryoablation catheter are feasible and safe with a high acute success rate. The need for coronary sinus ablation is reduced. A dual console technique is possible. Long-term durability of linear lesions remains to be determined.

Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front (STOP AF) pivotal trial

OBJECTIVES

This study sought to assess the safety and effectiveness of a novel cryoballoon ablation technology designed to achieve single-delivery pulmonary vein (PV) isolation.

BACKGROUND

Standard radiofrequency ablation is effective in eliminating atrial fibrillation (AF) but requires multiple lesion delivery at the risk of significant complications.

METHODS

Patients with documented symptomatic paroxysmal AF and previously failed therapy with ≥ 1 membrane active antiarrhythmic drug underwent 2:1 randomization to either cryoballoon ablation (n = 163) or drug therapy (n = 82). A 90-day blanking period allowed for optimization of antiarrhythmic drug therapy and reablation if necessary. Effectiveness of the cryoablation procedure versus drug therapy was determined at 12 months.

RESULTS

Patients had highly symptomatic AF (78% paroxysmal, 22% early persistent) and experienced failure of at least one antiarrhythmic drug. Cryoablation produced acute isolation of three or more PVs in 98.2% and all four PVs in 97.6% of patients. PVs isolation was achieved with the balloon catheter alone in 83%. At 12 months, treatment success was 69.9% (114 of 163) of cryoblation patients compared with 7.3% of antiarrhythmic drug patients (absolute difference, 62.6% [p < 0.001]). Sixty-five (79%) drug-treated patients crossed over to cryoablation during 12 months of study follow-up due to recurrent, symptomatic AF, constituting drug treatment failure. There were 7 of the resulting 228 cryoablated patients (3.1%) with a >75% reduction in PV area during 12 months of follow-up. Twenty-nine of 259 procedures (11.2%) were associated with phrenic nerve palsy as determined by radiographic screening; 25 of these had resolved by 12 months. Cryoablation patients had significantly improved symptoms at 12 months.

CONCLUSIONS

The STOP AF trial demonstrated that cryoballoon ablation is a safe and effective alternative to antiarrhythmic medication for the treatment of patients with symptomatic paroxysmal AF, for whom at least one antiarrhythmic drug has failed, with risks within accepted standards for ablation therapy. (A Clinical Study of the Arctic Front Cryoablation Balloon for the Treatment of Paroxysmal Atrial Fibrillation [Stop AF]; NCT00523978).